<qa>  What is the name of the study that is designed to assess the clinical utility of an early markerThis is a multicentre, multinational, open labeled, prospective, randomized, controlled phase II study designed to assess the clinical utility of an early marker driven change of anti-angiogenic treatment bevacizumab to aflibercept maintaining the chemotherapy backbone until definite radiological progression in first line treatment of patients with metastatic colorectal cancer. After completing the run in phase of the study, with at least 30 patients completing their first line treatment due to progression, secondary resection or toxicity and being evaluable for CAF analyses, the results will be reviewed by an Independent Data Monitoring Committee IDMC. Based on that review the decision to continue with, modify or cancel the randomized part will be made. 